title: Hormonal testing and pharmacologic treatment of erectile dysfunction: a clinical practice guideline from the American College of Physicians.
abstract: METHODS
  The American College of Physicians developed this guideline to present the available evidence on hormonal testing in and pharmacologic management of erectile dysfunction. Current pharmacologic therapies include phosphodiesterase-5 (PDE-5) inhibitors, such as sildenafil, vardenafil, tadalafil, mirodenafil, and udenafil, and hormonal treatment.
  
  
  METHODS
  Published literature on this topic was identified by using MEDLINE (1966 to May 2007), EMBASE (1980 to week 22 of 2007), Cochrane Central Register of Controlled Trials (second quarter of 2007), PsycINFO (1985 to June 2007), AMED (1985 to June 2007), and SCOPUS (2006). The literature search was updated by searching for articles in MEDLINE and EMBASE published between May 2007 and April 2009. Searches were limited to English-language publications. This guideline grades the evidence and recommendations by using the American College of Physicians' clinical practice guidelines grading system. RECOMMENDATION 1: The American College of Physicians recommends that clinicians initiate therapy with a PDE-5 inhibitor in men who seek treatment for erectile dysfunction and who do not have a contraindication to PDE-5 inhibitor use (Grade: strong recommendation; high-quality evidence). RECOMMENDATION 2: The American College of Physicians recommends that clinicians base the choice of a specific PDE-5 inhibitor on the individual preferences of men with erectile dysfunction, including ease of use, cost of medication, and adverse effects profile (Grade: weak recommendation; low-quality evidence). RECOMMENDATION 3: The American College of Physicians does not recommend for or against routine use of hormonal blood tests or hormonal treatment in the management of patients with erectile dysfunction (Grade: insufficient evidence to determine net benefits and harms).
authors.affiliation: American College of Physicians and University of Pennsylvania, Philadelphia, Pennsylvania 19106, USA. aqaseem@acponline.org
authors.forename: Amir
authors.initials: A
authors.lastname: Qaseem
authors.forename: Vincenza
authors.initials: V
authors.lastname: Snow
authors.forename: Thomas D
authors.initials: TD
authors.lastname: Denberg
authors.forename: Donald E
authors.initials: DE
authors.lastname: Casey
authors.forename: Mary Ann
authors.initials: MA
authors.lastname: Forciea
authors.forename: Douglas K
authors.initials: DK
authors.lastname: Owens
authors.forename: Paul
authors.initials: P
authors.lastname: Shekelle
mesh_terms: D000075202:Contraindications; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5 / Q000009:adverse effects / Q000627:therapeutic use*; D007172:Erectile Dysfunction / Q000175:diagnosis* / Q000188:drug therapy* / Q000209:etiology; D020249:Hormone Replacement Therapy / Q000009:adverse effects; D006801:Humans; D006966:Hyperprolactinemia / Q000150:complications / Q000175:diagnosis; D007006:Hypogonadism / Q000150:complications / Q000175:diagnosis; D008297:Male; D010410:Penile Erection / Q000187:drug effects; D011388:Prolactin / Q000097:blood; D013739:Testosterone / Q000097:blood / Q000172:deficiency / Q000627:therapeutic use*
chemical_list: D013739:Testosterone; D011388:Prolactin; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5